.png)
Agenzia Italiana del Farmaco
Monitoring of monoclonal antibodies for COVID-19: second report published - Monitoring of monoclonal antibodies for COVID-19: second report published
Monitoring of monoclonal antibodies for COVID-19: second report published
In implementation of the Decree of the Ministry of Health of 6 February 2021 (published in the Offical Gazette (GU) no. 32 of 8/2/21), the Italian Medicines Agency has established the monitoring registry of monoclonal antibodies for treatment of COVID-19. Therefore, this press release makes public the results of the monitoring through the AIFA registry, relating to the antibodies currently available: bamlanivimab (AIFA Resolution published in the GU no. 58 of 09.03.2021), bamlanivimab and etesevimab (AIFA Resolution published in the GU no. 66 of 17.03.2021), casirivimab and imdevimab (AIFA Resolution published in the GU no. 71 of 23.03.2021).
The centres authorised by the Regions to compile the AIFA registry are available at the following link.
Published on: 16 April 2021
Contacts
Via del Tritone, 181 00187 Roma
VAT number: 08703841000
Tax code: 97345810580
IPA AIFA code: aifa_rm
IPA UCB code: UFE1TR